Jeff Kindler
-
Dealmaking machine Sanofi to buy Avila for $800M (Morning Read)
The dealmaking machine that is Sanofi-Aventis is at it again, signing an oncology drug pact with Avila Therapeutics in Waltham, Massachusetts, worth $40 million up front and up to $154 million in milestone payments per program. Overall, the deal is valued at $800 million, according to FierceBiotech.
-
Obama hails bill averting doc pay cut… for now (Morning Read)
The U.S. House gave final approval on Thursday to a bill that would avert a 25 percent cut in Medicare payments to doctors by freezing reimbursement rates at current levels until the end of next year, reports the New York Times. President Obama, who hailed the nearly unanimous action by Congress, promised to sign the legislation.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Sagent plans $100M IPO for generic injectables (Morning Read)
Sagent Holding Co., the Schaumburg, Illinois, company that is developing generic injectable pharmaceuticals, has filed for a $100 million initial public offering just as a host of drug companies tap public capital markets, with many seeking to raise proceeds for research, according to the Wall Street Journal.
-
Kindler out, biopharma head Read in, at Pfizer (Morning Read)
Jeff Kindler, a lawyer tapped as a fresh face to lead drugmaker Pfizer out of its dodrums, is out, after just a little over four years as chairman and chief excutive, reports NPR’s health blog. Kindler’s executive bio already has been erased from Pfizer’s website. Ian C. Read, 57, head of the company’s global biopharmaceuticals operations, is in.